IGFBP4, an estrogen-regulated gene [15,64], is downregulated in tamoxifen-resistant cell lines [65], forms part of a molecular signature of poor prognosis ER-positive breast cancer [32], and could help to identify people who may benefit from endocrine therapy in ovarian cancer [66]. This evidence concerns the gene IGFBP4 and breast cancer.